Objective: To evaluate the rationality of different doses of 50 mg 6-mercaptopurine (6-MP) tablets

and explore their efficacy and adverse reactions in the treatment of childhood acute lymphoblastic leukemia (ALL). Methods: According to the 1/ 2

1/ 3

and 1/ 4 division method

50 mg 6-MP tablets were divided into three groups

with 10 tablets in each group. After division

the tablets were weighed and the means and standard deviations were calculated. According to the 6-MP medication situation

a total of 314 cases of ALL from March 2015 to December 2020 treated in our department were selected and divided into two groups. Group A was given 1/ 2 divided administration

and group B was given 1/ 4 divided administration. The age

gender

risk status

the relapse-free survival (RFS) and the occurrence of adverse events (AE) in the maintenance stage of the two groups of patients were compared.Results: There were three segmentation methods

1/ 2 segmentation was the closest to the target

and the degree of dispersion was the smallest; 1/ 3 and 1/ 4 division methods were far away from the target

and the degrees of dispersion were large. There was no significant difference in age

gender

and risk stratification between groups A and B. There was no significant difference in the 6-year RFS between the two groups of patients

and there was no significant difference in the AE between groups A and B. Conclusion: The 1/ 2 pill is a reasonable division method

and the corresponding dose can be obtained more accurately. The pill is relatively complete

and it is not easy to cause waste of medicine. Dosing with 1/ 2 tablet (25 mg) as the smallest division unit or 1/ 4 tablet (12. 5 mg) as the smallest division unit has no effect on the long-term survival rate of patients. The two different administration methods have not increased the adverse effects of 6-MP.